[EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS [FR] AZA-HÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES EN TANT QUE MODULATEURS DES SIRTUINES
[EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS [FR] AZA-HÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES EN TANT QUE MODULATEURS DES SIRTUINES
Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
申请人:GlaxoSmithKline, LLC
公开号:US20140249147A1
公开(公告)日:2014-09-04
Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
申请人:GlaxoSmithKline LLC
公开号:EP2768834A1
公开(公告)日:2014-08-27
[EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS<br/>[FR] AZA-HÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES EN TANT QUE MODULATEURS DES SIRTUINES
申请人:SIRTRIS PHARMACEUTICALS INC
公开号:WO2013059589A1
公开(公告)日:2013-04-25
Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.